XBiotech Inc. (XBIT)

♥ 590 Thanks from members

XBiotech Inc. (XBIT) displays cautious sentiment, driven by lower R&D expenses and a Phase II trial for vilamakitug, offset by ongoing net losses, zero revenue, and four consecutive quarters of institutional selling.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: John Simard Leadership: John Simard (CEO) Leadership: Queena Han (CFO) Holder: XBiotech Inc. Insiders Holder: The Vanguard Group Holder: Renaissance Technologies Natrunix True Human Monoclonal Antibodies Anti-IL-1alpha therapies #XBIT stock #XBiotech Inc #True Human antibodies #NASDAQ XBIT #biotech clinical stage